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Abstract
Rheumatoid Arthritis (RA) is a systemic, chronic inflammatory 
disease characterized by inflammation of synovial joints and 
production of autoantibodies such as Rheumatoid Factor and 
antibodies directed against modified proteins - i.e. anti-citrullinated 
peptides antibody (ACPA). Carbamylation, as a post translational 
modification, has been recently associated to RA since anti-
carbamylated protein antibodies (anti-CarP) have been detected in 
the sera of RA patients. The effect of treatment on anti-CarP level 
has been never addressed before.
Through this study we aimed to investigate the short term effect 
of anti-TNF treatment with Etanercept on anti-CarP. We enrolled 
consecutive RA patients before starting treatment with Etanercept. 
Clinical data and serum samples were gathered from each patient 
at baseline and after 3 months of treatment. Disease activity was 
assessed at baseline and after 3 months by using the C-reactive 
protein - Disease Activity Score (DAS) 28. Sixty-three age and sex 
matched healthy donors served as controls. Anti-Car-P antibodies 
were investigated by immune-enzymatic assay.
We enrolled 17 RA patients (F:M 15:2, mean age 44.1 ± 10.7 years, 
mean disease duration 7.9 ± 5.8 years). Six patients (35.3%) were 
positive for anti-CarP antibodies at baseline while three months 
after only 4 patients (23.5%) remained positive. Mean serum level 
of anti-CarP antibodies at baseline and after 3 months were: 253.0 
± 139.8AU/ml and 271.0 ± 132.4AU/ml respectively. Considering 
the persistently anti-CarP positive patients, the mean antibody titre 
increases from 386.2 ± 49.3AU/ml at baseline to 421.8 ± 144.0AU/
ml at follow up.
The effect of anti-TNF treatment on autoantibody status is still 
controversial; in particular, data on ACPA variation during treatment 
are discordant. In our cohort of long standing RA patients, a short 
term course of Etanercept did not affect the antiCarP status.
In conclusion, this pilot study demonstrated a slight reduction in the 
percentage of anti-CarP positive patients but an overall increase 
of antibody titre unrelated to the clinical response to TNF blockade 
was observed.
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Introduction
Rheumatoid Arthritis (RA) is a systemic, chronic inflammatory 
disease mainly affecting the synovial joints, leading to cartilage 
and bone erosion. A distinctive feature of RA is the production of 
autoantibodies such as Rheumatoid Factor (RF) and antibodies 
directed against modified proteins - i.e. anti-citrullinated peptides 
antibody (ACPA).
Post-translational modifications encompass several enzymatic 
or chemical reactions that modify and modulate protein functions. 
Among the others, carbamylation of proteins, leading to the 
production of homocitrulline, have been recently associated to 
RA. Anti-carbamylated proteins (anti-CarP) antibodies have been 
proposed as an additional biomarker of RA, especially in seronegative 
subjects and even in pre-clinical stage. As previously demonstrated 
for ACPA [1], anti-CarP antibodies seems to have a prognostic role 
since their presence is associated to a more severe and aggressive 
disease course [2].
The effect of treatment of anti-CarP in RA patients has never 
been addressed up to now. In the present study our objective was to 
investigate the short term effect of anti-TNF treatment on anti-CarP 
serum levels.
Patients and Methods
Consecutive RA patients who were due to start treatment with 
Etanercept were enrolled. Patients with known cardiovascular 
disease (CVD) or kidney failure were excluded. Serum samples were 
collected at baseline and after 3 months of therapy, aliquoted and 
stored at -20°C until tested.
Disease activity was assessed at baseline and after 3 months by 
C-reactive protein (CRP) - Disease Activity Score (DAS)28.
Anti-CarP antibodies were investigated by a “home-made” ELISA 
as previously reported [2] using carbamylated Fetal Calf Serum (FCS) 
(Car-FCS) and unmodified FCS as antigens. A titration curve of two 
positive reference sera with medium-high ELISA immunoreactivity 
for anti-Car-FCS was carried out in order to show the performance 
of the test and to transform the absorbance of Car-FCS to arbitrary 
units per milliliter (aU/mL). The cut-off was established as the mean 
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value + 3 standard deviation of 63 healthy donors.
The objective of this study was exploratory and no appropriate 
information to base a sample size was available. Data presented 
a normal distribution and were expressed as mean ± standard 
deviation. Differences in quantitative variables were analysed by 
the Student’s t test while Pearson’s correlation coefficient was used 
to assess correlation between other variables. P values <0.05 were 
considered statistically significant.
Results
In this pilot study we enrolled 17 patients with long standing RA 
fulfilling the 2010 ACR criteria [3]. Concomitant therapy remained 
stable throughout the 3 months of follow-up in all the patients. Table 
1 reports demographic and clinical data of the cohort.
At baseline, 6 patients (35.3%) were positive for ant-CarP 
antibodies; at follow-up, 4 patients were still positive (23.5%) while 
2 patients turned negative. Mean serum level of anti-CarP antibodies 
in the whole cohort was 253.0 ± 139.8 AU/ml at baseline and 271.0 
± 132.4 AU/ml at the third month of Etanercept treatment. (Figure 
1). Considering the sub-population of anti-CarP positive patients, the 
mean antibody titre was 386.2 ± 49.3 AU/ml at baseline and increased 
to 421.8 ± 144.0 AU/ml after 3 months (Figure 1). After 3 months 
of anti-TNF treatment with Etanercept we detected a significant 
decrease of DAS28 (5.14 ± 1.3 to 3.73 ± 1.3, p=0.003).
At baseline, anti-CarP positive patients presented with a high 
disease activity (DAS28=5.9 ± 1.2). All the 4 patients persistently 
positive for anti-CarP showed a clinically meaningful reduction 
of DAS28 (-2.8 ± 2.3) and were considered EULAR moderate 
responders; one of them was considered in remission, another one 
showed a low disease activity and the remaining two a moderate 
disease activity. We did not find any correlation between anti-CarP 
serum level and DAS28 at baseline nor at follow-up.
Discussion
This pilot study is the first attempt to investigate a possible effect 
of anti-TNF treatment on anti-CarP status. A short term course of 
Etanercept seems not to affect antiCarP serum levels in a small cohort 
of RA patients.
Post-translational modifications of self-antigens are responsible 
for the formation of neo-epitopes that give rise to (auto)-antibodies 
formation. Besides RF and ACPA, anti-CarP antibodies have 
recently gained interest as additional diagnostic and prognostic 
marker of RA. Carbamylation is a post-translational modification 
in which cyanate binds to amino or thiol groups; this modification 
is determined by increase of blood urea nitrogen levels (i.e. kidney 
failure), inflammation [4] or enzymatic conversion of lysine residues 
into homocitrulline [5].
Recently, Shi et al. [2] started to investigate the immunogenicity 
to homocitrullinated peptides in RA. Antibodies to carbamylated 
proteins were detected both in ACPA positive and ACPA 
negative patients suggesting that anti-citrullinated peptide and 
anti-homocitrullinated peptides are two separate families of 
autoantibodies; however, the authors did not definitively exclude 
F:M 15:2
Age
Mean ± SD (range), yrs
44.1 ± 10.7 
(28-63)
Disease duration
Mean ± SD (range), yrs
7.9 ± 5.8
(2.5-23) 
BMI mean ± SD 27.3 ± 12.3
Smoking habit N(%) 3/17 (17.6)
Glucocorticoids N(%) 17/17 (100)
Methotrexate N(%) 12/17 (70.6)
Hydroxychloroquine N(%) 2/17 (11.8)
Leflunomide N(%) 1/17 (5.9)
Table 1: Demographic and clinical data of the 17 RA patients
         
Figure 1: Variation of anti-CarP serum levels during Etanercept treatment in the whole cohort of patients with Rheumatoid Arthritis (left) and in the sub-group 
of positive patients (right).
• Page 3 of 3 •Spinelli et al. J Rheum Dis Treat 2015, 1:2
certain cross-reactivity between the two classes of antibodies [2]. 
Moreover, anti-CarP showed a strong association with an erosive 
disease, especially in seronegative patients [2].
Like RF and ACPA [6,7], even anti-CarP can precede the clinical 
onset of RA. Reactivity to carbamylated-FCS was detected in 39% 
of patients with inflammatory arthralgia who develop an overt RA 
within a median time of 12 months [8]. Moreover, anti-CarP (FCS 
and fibrinogen) were detected in sera collected from healthy subjects 
many years before the development of RA. The detection of anti-CarP 
in pre-clinical and early stage of the disease suggests a role - still not 
fully elucidated - for these antibodies in the pathogenesis of RA.
The effect of treatment on anti-CarP status is still not known. To 
the best of our knowledge, the present study is the first one aimed 
to investigate the short term effect of TNF inhibition on anti-CarP 
serum levels. It was not possible to observe a significant variation 
of anti-CarP levels in the 17 long-standing RA patients treated 
with Etanercept. Data on the effect of anti-TNF drugs on ACPA 
and relationship between decrease of ACPA and clinical response 
are somehow controversial. In 2004, Alessandri et al were among 
the first to investigate the effect of TNF inhibition on ACPA and 
demonstrate a decrease titres of RF and ACPA in patients showing 
clinical improvement [9]. In the last decade, many authors addressed 
the same topic showing contrasting results: some authors identified a 
reduction of ACPA levels while other did not detected any effect of 
anti-TNF drugs on ACPA titre [10].
Unexpectedly, in our cohort we observed an increase of anti-CarP 
serum levels, not correlating with the disease activity. The relationship 
between anti-CarP titres and response to treatment is still unknown. 
The results of this pilot study suggest a dissociation between serum 
levels of anti-CarP and reduction of disease activity even in patients 
who showed an increase of antibody titres after anti-TNF treatment.
Disease duration seems to be one of the factors affecting ACPA 
response during anti-TNF therapy: shorter disease duration (less than 
one year) was more likely associated to autoantibodies negativization 
[10]. The long disease duration of the cohort described in the present 
study might have influenced the low variation of anti-CarP during the 
follow-up. The results of this study should be interpreted cautiously 
since this is a pilot study on a small cohort of patients. Moreover, 
the short term of the observation could be insufficient to catch a 
modification of antibody titre.
In conclusion, this pilot study aimed at evaluating the short term 
effect of anti-TNF on anti-CarP serum levels and status showed a 
slight reduction of percentage of positive patients but an overall 
increase of antibody titres unrelated to the clinical response to TNF 
blockade.
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